abnormalities in specific brain regions; however, the extent to which brain network topology is altered by OAB remains unknown. The aim of this study is to use functional magnetic resonance imaging (fMRI) to explore brain small-world network changes during bladder filling in women with OAB as well as in healthy controls. To our knowledge, this is the first study to apply the concepts of small-world brain network topology to micturition.
INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) is commonly used for the management of localized and metastatic prostate cancer. There is mounting evidence that ADT may expedite loss of brain volume, which may hasten cognitive decline. In this study we aim to quantify the loss of cortical brain volume in patients on ADT.
METHODS: We retrospectively analyzed baseline and follow up CT head scans of 14 men prior to and after initiation of ADT. Men underwent CT head imaging for non-trauma/ischemic indications. All CT imaging were reviewed using 3D planimetry software (3D Splicer Ò, Version 4.0). Brain, ventricular surface area and volumes were assessed via segmentation protocol. All volumes and surface areas were calculated using dedicated, automated software ( Figure) . Baseline socio-demographic variables, comorbidities, and risk factors were collected retrospectively. Paired t-test was utilized to assess change in brain volume prior to and after initiation of ADT RESULTS: A total of 14 patients were analyzed in the study. Mean age 74.36 yo (AE13.76), with median ADT duration of 9.5 months (IQR 6.0, 16.25) , with a median washout period of 11 months ( IQR 6.5, 20.25) prior to follow up CT scan. Overall, 5 (35.7%) and 9 (64.3%) were started on either Leuprolide acetate plus Bicalutamide, vs Leuprolide acetate alone, respectively. Additionally, 6 (42.9%) had oligo-metastatic disease to the bone at the time of ADT initiation.
Compared to baseline CT imaging, patients on ADT experienced statistically significant brain volume loss p[0.027) INTRODUCTION AND OBJECTIVES: High resolution microultrasound (micro-US) is a novel technology which offers the potential to image PCa and perform targeted biopsies with significantly improved cancer visualization compared to conventional ultrasound, potentially obviating the need for MRI. Micro-US incorporates a scoring system (PRIMUS, Grades 1-5) that is similar to the PIRADS-2 system used for MRI. This facilitates assignment of a risk category based on the characteristics of the region of interest. We evaluate the NPV and PPV for each PRIMUS risk category.
METHODS: 50 patients underwent prostate biopsy using micro-US (ExactVu micro-US, Exact Imaging, Markham, Canada). 32 were undiagnosed men at risk for PCa, and 18 had been previously treated with focal therapy with HIFU or TULSA and were undergoing post treatment biopsies. In the undiagnosed patients, targeted and 12 core systematic biopsies were performed. 28 had had a prior MRI. Physicians were blinded to the MRI results at the time of biopsy. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e393 RESULTS: The NPV for PRIMUS scores <[ 3 for clinically significant PCa was 96% (27/29). Of 19 cases with a PRIMUS 4 or 5 lesion, 63% had a positive biopsy. In 10 cases with GG !2, 9 (90%) had a PRI-MUS !3 lesion at the cancer location. The single GG ! 2 cancer missed on micro-US was a post-focal therapy case whose MRI was also negative.
Of 28 cases who had both MRI and micro-US, 12 had a positive biopsy. 7/12 had targets seen on both modalities. 1/12 was negative on both; 4/12 had GG 2 with a positive micro-US and negative MRI. All patients with a PIRADS score 4-5 had a PRIMUS 4-5 lesion on micro-US at the same location. The PPV for each PRIMUS score for all PCa grades was 1: 0%, 2: 33%, 3: 29%, 4: 63%, 5: 67%, and for GG 2, 1: 0%, 2: 0%, 3: 4%, 4:38%, 5: 67%.
CONCLUSIONS: High resolution micro-ultrasound with targeted biopsy appears to offer comparable sensitivity, specificity, PPV and NPV to MP-MRI, in the setting of both primary diagnosis and posttreatment recurrence. Micro-ultrasound-based biopsies combine imaging and targeting in a single session and involves substantially less cost and complexity than MRI combined with fusion targeting. METHODS: 1,676 men indicated for prostate biopsy and without known prostate cancer were randomized 1:1 to micro-US or conv-US guided biopsy at 5 sites in North America from 2013-16. Exactly 12-cores were taken transrectally from each subject, with each core taken either systematically or from a target near the systematic position. The trial was paused after 1,113 subjects to train investigators on the new PRI-MUS TM (Prostate Risk Identification using Micro-Ultrasound) protocol for micro-US targeting, developed using data from the first portion of the trial. csPCA was defined as any Gleason Grade Group > 1 and/or any core with > 50% cancer.
RESULTS: The per-patient detection rates of csPCA in the intent-to-treat (ITT) analysis did not differ between transrectal micro-US and conv-US arms (34.6% (290/837) vs. 36.6% (307/839), respectively, p[0.21). However, the per-protocol analysis (PP) detection rate of csPCA was significantly greater with micro-US (43.7% (125/286) vs. 36.6% (301/823), p[0.02). After PRI-MUS training, sensitivity improved to 63.4% from 24.7% for micro-US (p<0.01), but at the cost of lower specificity (post-training for micro-US [ 61.7%, conv-US [ 89.5%), suggesting a learning curve to micro-US interpretation across all investigators. Unexpected prostate under-sampling was noted in the micro-US arm, where 65.8% of men had inadequate sampling of the prostatic apex, which explains the disparity in number of subjects between the ITT and PP groups.
CONCLUSIONS: First generation transrectal micro-US with PRI-MUS achieved greater sensitivity to detect significant prostate cancers than conventional TRUS. Despite limitations of the firstgeneration instrument, when clinicians were instructed in micro-US image interpretation and used proper systematic biopsy technique with the experimental probe, greater cancer detection rates were achieved with the same number of biopsy samples. This work also represents the first prospective validation of a protocol for real-time lesion identification and biopsy targeting using micro-US (PRI-MUS).
Additional studies are underway to refine use and application of this novel imaging technology.
Source of Funding: Exact Imaging (Trial sponsor)
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INTRODUCTION AND OBJECTIVES: Non-contrast computed tomography (NCCT) is the imaging modality of choice in evaluating patients with urolithiasis. In the absence of hydronephrosis or a delayed contrast phase, delineation of the collecting system is not possible. Thus, the surgical plan may not be fully devised until a retrograde pyelogram is performed at the time of surgery. The combination of hydration and furosemide has been shown to improve visualization of the upper urinary tract during contrast-enhanced CT imaging. We evaluated the effect of the DRINK protocol (pre-imaging oral hydration and a single oral dose of furosemide) on delineation of the collecting system during NCCT.
METHODS: In this prospective, non-randomized study, each participant's pre-existing NCCT scan served as a control. For the study NCCT, each patient was instructed to drink one liter of water and take 20 mg of oral furosemide within the hour prior to their study. A distension score was given for three segments (upper, middle, and lower infundibula) in the axial, coronal, and sagittal views of the nonaffected kidney. Scores (0-3) were based on the percentage of the segment that was distended compared to the prior non-DRINK NCCT (0[0%; 1[<50%; 3[100%) . Images were scored by a radiologist and two fellowship trained endourologists. Distension scores for both the control and DRINK hydration protocol were compared. The nonparametric Wilcoxon signed-rank test was used to test for statistical change.
RESULTS: Among 15 study patients, collecting system distension scores were significantly higher after the hydration and lasix protocol when compared to the images from their past non-DRINK NCCT scans (p<0.05) ( Table 1 ). This pattern of statistically significant change extended across all image views (axial, coronal, and sagittal) and all infundibula (upper, middle, and lower).
CONCLUSIONS: Hydration and furosemide given an hour prior to NCCT (i.e. DRINK protocol) result in a measurably increased distension of the collecting system.
